Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.

Archivum immunologiae et therapiae experimentalis - 1 Dec 2016

Butrym Aleksandra, Łacina Piotr, Rybka Justyna, Chaszczewska-Markowska Monika, Mazur Grzegorz, Bogunia-Kubik Katarzyna

Abstract excerpt

Multiple myeloma (MM) is a plasma-cell malignancy derived from an early precursor of the B-cell lineage characterised by bone-marrow infiltration, lytic bone lesions, and the presence of a monoclonal protein in serum and/or urine. Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator in B-cell development and function that is required during immune response for lymphocyte activation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B-Lymphocytes
Share to Immune System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon Regulatory Factors

Share to Multiple Myeloma

Share to Peptide Hydrolases

Share to Poland

Share to Thalidomide

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 28083618
DOI: 10.1007/s00005-016-0442-6
PMCID: PMC5334380

Genes

CRBN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.PMID 28083618Read ↗

Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Identification of miRSNPs associated with the risk of multiple myeloma.Semantic proximity Read ↗

Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.Semantic proximity Read ↗

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read ↗

Cereblon enhancer methylation and IMiD resistance in multiple myelomaSemantic proximity Read ↗

Germline and somatic genetic effects on gene expression and outcome in patients with Multiple MyelomaSemantic proximity Read ↗

Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma.Semantic proximity Read ↗

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic markerSemantic proximity Read ↗

IRF4 in multiple myeloma—Biology, disease and therapeutic targetSemantic proximity Read ↗

IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.Semantic proximity Read ↗

A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.Semantic proximity Read ↗

Deciphering the genetics and mechanisms of predisposition to multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.